From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Topics>
  3. Hepatitis

Hepatitis

The latest information on cirrhosis, interferon, ribavirin, vaccines, and more, drawn from across our primary care and specialty care areas. Sign up now for monthly e-mail alerts on new content.

SUMMARY AND COMMENT

Sofosbuvir Works for Patients Who Cannot Take PeginterferonFree

Two phase III studies confirm the efficacy of a sofosbuvir and ribavirin therapy in patients with HCV genotype 2 or 3 infection for whom peginterferon is not an option.

SUMMARY AND COMMENT

Predictors of Poor Outcomes in Autoimmune Hepatitis

Liver-related death or need for liver transplantation was associated with age at presentation, incomplete treatment response, and low albumin, but not advanced fibrosis.

SUMMARY AND COMMENT

A Global View of HCV Infection and Barriers to Treatment

Even with new treatments on the horizon for HCV infection, worldwide issues of access, cost, and gaps in physician knowledge must be addressed.

SUMMARY AND COMMENT

Sofosbuvir-Based Therapy for HCV Infection: The Results Are In

The evidence shows superior efficacy and tolerability of sofosbuvir-based regimens versus those currently available, particularly in patients with HCV genotype 1.

SUMMARY AND COMMENT

Does HBV Suppression with Entecavir Affect Clinical Outcomes?Free

Evidence from an ongoing prospective cohort study indicates yes, but only in patients with cirrhosis, and only when virologic response is strong.

SUMMARY AND COMMENT

Sofosbuvir plus Peginterferon and Ribavirin for Chronic HCV InfectionFree

In phase II trials, a 12-week regimen resulted in high virologic response 24 weeks after treatment, no sofosbuvir-specific adverse effects, and no virologic breakthrough. CME

SUMMARY AND COMMENT

Where Are We with Pentoxifylline for Severe Alcoholic Hepatitis?

A pooled analysis of available trial data showed a 53% reduction in mortality from hepatorenal syndrome, but no reduction in overall mortality, compared with placebo.

SUMMARY AND COMMENT

Targeting Host Cell MicroRNA: An Exciting New Approach to HCV Treatment

A drug that sequesters a liver-cell microRNA decreases HCV RNA — in some cases, to undetectable levels.

SUMMARY AND COMMENT

Transient Elastography Might Replace Liver Biopsy in HCV Management

This non-invasive procedure had a sensitivity of 100% and a specificity of 89% in identifying patients with cirrhosis at a cutoff point of 13.1 kPa. CME

SUMMARY AND COMMENT

Hepatitis C Virus Seldom Is Transmitted Sexually

This study should reassure monogamous heterosexual couples who are discordant for the virus.

Read more Hepatitis articles >>

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

Browse arrow

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Copyright © 2013. Massachusetts Medical Society. All rights reserved.